Clinical Perspective on Antibiotic Resistance, Collaboration among Stakeholders
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 145
Special Issue Editor
Interests: antibiotics in clinical practice; antibiotic resistance; antibiotic stewardship; nosocomial infections; global health; infections diseases; SARS-CoV-2 infection
Special Issue Information
Dear Colleagues,
Antibiotic resistance (ABR) is a hierarchical challenge of global health, which has long been recognized by international health agencies, such as the WHO, and non-health agencies, such as the International Monetary Fund (IMF), the World Bank, as well as the G7. Although the clinical implications of healthcare-associated infections due to multidrug-resistant pathogens remain unclear, they are highly heterogeneous in their etiology and clinical presentations. In the United States for example, VRE, carbapenem-resistant Acinetobacter species, and MDR P. aeruginosa are identified almost exclusively among patients with considerable healthcare exposure, and such resistance exposure appears to be rarely acquired in the community. Current trends suggest that the incidence of carbapenem-resistant Enterobacteriaceae is somehow stable, whereas the incidence of ESBL has increased. Healthcare practitioners are encouraged to understand and synthesize mechanisms by which antibiotic resistance emerges and how to apply knowledge of ABR to their daily practice in anticipation of minimizing the risk of ABR. In particular, it is critical to apply knowledge of clinically important ABR genes to clinical practice. In this respect, the role of clinical microbiology labs is pivotal in establishing close working relationships with healthcare practitioners developing robust guidelines for the identification of resistant genes from Gram-positive and Gram-negative pathogens as well as the evaluation of patients with a history of resistance to single or multiple antibiotics in order to improve clinical outcomes.
Prof. Dr. Reza Nassiri
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- global health
- antibiotic resistance
- clinically important resistance genes
- role of clinical microbiology labs
- knowledge-based applications minimizing ABR
